Terms: = Sarcomas AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Treatment
82 results:
1.
de Traux de Wardin H; Dermawan JK; Vanoli F; Jiang SC; Singer S; Chi P; Tap W; Wexler LH; Antonescu CR
JCO Precis Oncol; 2024 Apr; 8():e2300597. PubMed ID: 38603649
[TBL] [Abstract] [Full Text] [Related]
2. A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced nras-mutant melanoma.
Wei X; Zou Z; Zhang W; Fang M; Zhang X; Luo Z; Chen J; Huang G; Zhang P; Cheng Y; Liu J; Liu J; Zhang J; Wu D; Chen Y; Ma X; Pan H; Jiang R; Liu X; Ren X; Tian H; Jia Z; Guo J; Si L
Eur J Cancer; 2024 May; 202():114008. PubMed ID: 38479118
[TBL] [Abstract] [Full Text] [Related]
3. Using tumor habitat-derived radiomic analysis during pretreatment
Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres.
Pallocca M; Molineris I; Berrino E; Marcozzi B; Betti M; Levati L; D'Atri S; Menin C; Madonna G; Ghiorzo P; Bulgarelli J; Ferraresi V; Venesio T; Rodolfo M; Rivoltini L; Lanfrancone L; Ascierto PA; Mazzarella L; Pelicci PG; De Maria R; Ciliberto G; Medico E; Russo G
J Transl Med; 2024 Jan; 22(1):29. PubMed ID: 38184610
[TBL] [Abstract] [Full Text] [Related]
5. The diagnosis and treatment for primary cardiac angiosarcoma with n-ras gene mutation and MSI-L: A case report and review of the literature.
Sun J; Wei T; Sun B; Su J; Liu H; Wang D; Li X
Medicine (Baltimore); 2023 Dec; 102(51):e36682. PubMed ID: 38134104
[TBL] [Abstract] [Full Text] [Related]
6. Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities.
Creus-Bachiller E; Fernández-Rodríguez J; Magallón-Lorenz M; Ortega-Bertran S; Navas-Rutete S; Romagosa C; Silva TM; Pané M; Estival A; Perez Sidelnikova D; Morell M; Mazuelas H; Carrió M; Lausová T; Reuss D; Gel B; Villanueva A; Serra E; Lázaro C
Mol Oncol; 2024 Apr; 18(4):895-917. PubMed ID: 37798904
[TBL] [Abstract] [Full Text] [Related]
7. Small molecular inhibitors for KRAS-mutant cancers.
Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
[TBL] [Abstract] [Full Text] [Related]
8. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue sarcomas: Mutational Signature Analysis and Immunotherapy Response.
Kasago IS; Chatila WK; Lezcano CM; Febres-Aldana CA; Schultz N; Vanderbilt C; Dogan S; Bartlett EK; D'Angelo SP; Tap WD; Singer S; Ladanyi M; Shoushtari AN; Busam KJ; Hameed M
Mod Pathol; 2023 Aug; 36(8):100165. PubMed ID: 36990277
[TBL] [Abstract] [Full Text] [Related]
9. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
[TBL] [Abstract] [Full Text] [Related]
10. A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced nras-mutant melanoma.
Mao L; Guo J; Zhu L; Jiang Y; Yan W; Zhang J; Hui AM; Yang Y; Diao L; Tan Y; Zhao H; Jiang Y; Wu Z; Si L
Eur J Cancer; 2022 Nov; 175():125-135. PubMed ID: 36113242
[TBL] [Abstract] [Full Text] [Related]
11. Prevalence and detection of actionable BRAF V600 and nras Q61 mutations in malignant peripheral nerve sheath tumor by droplet digital PCR.
Kao EY; Wakeman KM; Wu Y; Gross JM; Chen EY; Ricciotti RW; Liu YJ; Mantilla JG
Hum Pathol; 2022 Nov; 129():90-97. PubMed ID: 36067829
[TBL] [Abstract] [Full Text] [Related]
12. Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an
Shaheen MF; Tse JY; Sokol ES; Masterson M; Bansal P; Rabinowitz I; Tarleton CA; Dobroff AS; Smith TL; Bocklage TJ; Mannakee BK; Gutenkunst RN; Bischoff J; Ness SA; Riedlinger GM; Groisberg R; Pasqualini R; Ganesan S; Arap W
Elife; 2022 Jul; 11():. PubMed ID: 35787784
[TBL] [Abstract] [Full Text] [Related]
13. Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma.
Zhao H; Dong Z; Wan D; Cao W; Xing H; Liu Z; Fan J; Wang H; Lu R; Zhang Y; Cheng Q; Jiang Z; He F; Xie X; Guo R
Sci Rep; 2022 Apr; 12(1):6752. PubMed ID: 35474239
[TBL] [Abstract] [Full Text] [Related]
14. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Odeniyide P; Yohe ME; Pollard K; Vaseva AV; Calizo A; Zhang L; Rodriguez FJ; Gross JM; Allen AN; Wan X; Somwar R; Schreck KC; Kessler L; Wang J; Pratilas CA
Oncogene; 2022 May; 41(21):2973-2983. PubMed ID: 35459782
[TBL] [Abstract] [Full Text] [Related]
15. Morbidity and long-term results in patients with wild and mutant type Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations undergoing colorectal cancer surgery.
Aziret M; Subasi O; Bilir C; Tozlu M; Altıntoprak F; Karaman K; Ercan M; Celebi F
Ann Ital Chir; 2022; 92():65-77. PubMed ID: 35342104
[TBL] [Abstract] [Full Text] [Related]
16. Near Complete Response to Trametinib treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation.
Hu B; Patel JL; Tao R; Cannon RB; Monroe M; Goyal G
J Natl Compr Canc Netw; 2022 Mar; 20(6):618-621. PubMed ID: 35325867
[TBL] [Abstract] [Full Text] [Related]
17. Myeloid Sarcoma Involving the Testis in Adults: Clonal Evolution of Acute Myeloid Leukemia.
Nichols MM; Cook JR; Bosler DS; Rogers HJ; Philip JKSS; Jogenpally NR; Reynolds JP; Robertson S; Cotta CV
Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):e32-e39. PubMed ID: 35001036
[TBL] [Abstract] [Full Text] [Related]
18. Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data.
Zhang X; Jin F; Jiang S; Cao J; Meng Y; Xu Y; ChunmengWang ; Chen Y; Yang H; Kong Y; Liu X; Luo Z
Invest New Drugs; 2022 Apr; 40(2):453-460. PubMed ID: 34731354
[TBL] [Abstract] [Full Text] [Related]
19. Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients.
Diaz Coronado RY; Mynarek M; Koelsche C; Mora Alferez P; Casavilca Zambrano S; Wachtel Aptowitzer A; Sahm F; von Deimling A; Schüller U; Spohn M; Sturm D; Pfister SM; Morales La Madrid A; Sernaque Quintana R; Sarria Bardales G; Negreiros Chinchihuara T; Ojeda Medina L; Garcia-Corrochano Medina P; Campos Sanchez DA; Ponce Farfan J; Rutkowski S; Garcia Leon JL
Cancer; 2022 Feb; 128(4):697-707. PubMed ID: 34674226
[TBL] [Abstract] [Full Text] [Related]
20. Inhibiting the "Undruggable" RAS/Farnesyltransferase (FTase) Cancer Target by Manumycin-related Natural Products.
Silva LR; da Silva-Júnior EF
Curr Med Chem; 2022; 29(2):189-211. PubMed ID: 33719954
[TBL] [Abstract] [Full Text] [Related]
[Next]
